Brigham Young University

BYU ScholarsArchive
Theses and Dissertations
2018-08-01

The Effect of Mechanical Load on Biomarkers of Knee Joint
Inflammation for Individuals Who Are Predisposed to Knee
Cartilage Degeneration: An Exploratory Study
Alyssa Evans
Brigham Young University

Follow this and additional works at: https://scholarsarchive.byu.edu/etd
Part of the Life Sciences Commons

BYU ScholarsArchive Citation
Evans, Alyssa, "The Effect of Mechanical Load on Biomarkers of Knee Joint Inflammation for Individuals
Who Are Predisposed to Knee Cartilage Degeneration: An Exploratory Study" (2018). Theses and
Dissertations. 7560.
https://scholarsarchive.byu.edu/etd/7560

This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion
in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please
contact scholarsarchive@byu.edu, ellen_amatangelo@byu.edu.

The Effect of Mechanical Load on Biomarkers of Knee Joint Inflammation
for Individuals Who Are Predisposed to Knee Cartilage Degeneration:
An Exploratory Study

Alyssa Evans

A thesis submitted to the faculty of
Brigham Young University
in partial fulfillment of the requirements for the degree of
Master of Science

Matthew K. Seeley, Chair
Robert D. Hyldahl
J. Ty Hopkins

Department of Exercise Sciences
Brigham Young University

Copyright © 2018 Alyssa Evans
All Rights Reserved

ABSTRACT
The Effect of Mechanical Load on Biomarkers of Knee Joint Inflammation
for Individuals Who Are Predisposed to Knee Cartilage Degeneration:
An Exploratory Study
Alyssa Evans
Department of Exercise Sciences, BYU
Master of Science
Objective
Physical exercise decreases disability and pain associated with chronic articular cartilage
degradation. However, understanding of the pathology is lacking. In this study, the levels of 17
biomarkers of inflammation and cartilage degradation were measured in synovial fluid (SF)
before and after a 30-minute run in able-bodied and previously-injured individuals.
Materials & Methods
Four able-bodied recreational runners (3 men and 1 woman: 24 ± 2 years, 68 ± 7 kg, and
173 ± 9 cm) and 4 recreational runners who had undergone a unilateral anterior cruciate ligament
reconstruction (ACLr) (2 men and 2 women: 23 ± 1 years, 71 ± 6 kg, and 175 ± 4 cm) were
recruited to participate in this study. Using a saline-assisted method, SF was aspirated before and
after both a 30-minute unloading and 30-minute exercise session. Samples were corrected for
blood contamination and analyzed for 15 cytokines and 2 matrix metalloproteinases (MMPs).
Mixed model analyses were used to determine the main effects of session, case/control status,
pre/post aspirations, and the interactions between case/control status and pre/post aspirations.
Results

Blood protein contamination was calculated and accounted for in 15 of 32 synovial fluid
samples. Granulocyte colony stimulating factor (GCSF) was the only detectable cytokine of the
15 analyzed. No statistical differences were found in GCSF concentrations between pretreatment
and posttreatment aspirations (p = 0.45), ACLr and able-bodied control groups (p = 0.60), or
unloading and exercise sessions (p = 0.96). MMP-13 was undetectable. No statistical differences
were found in MMP-3 between pretreatment and posttreatment aspirations (p = 0.15), ACLr and
able-bodied control groups (p = 0.85), or unloading and exercise sessions (p = 0.14).
Conclusions
Two (GCSF and MMP-3) of the 17 measured biomarkers were detectable. There were no
significant differences in either GCSF or MMP-3 due to a 30-minute run or 30-minute unloading
period in either the able-bodied or ACLr participants. Further, there were no significant
differences between biomarker concentrations and case-control status. A novel method of
controlling for blood contamination in synovial fluid samples was implemented.
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INTRODUCTION
Chronic degradation of healthy knee articular cartilage is a common problem that leads to
osteoarthritis (OA), the most common joint disease worldwide. There is currently no cure for
chronic articular cartilage degeneration (ACD).1 ACD can be painful and debilitating and it
affects 10% of men and 18% of women over the age of 60.2 Factors that influence chronic ACD
progression are numerous and unclear. However, accumulating evidence suggests that the onset
and progression of chronic ACD are partly influenced by knee joint load.3–5 Joint biochemistry is
another factor that is thought to influence ACD onset and progression. Increased, low-grade
synovial inflammation is believed to precede structural degeneration6–8. Further, chronic intraarticular inflammation is a reliable predictive measure of ACD progression in early-stage
patients9. Granulocyte-macrophage colony-stimulating factor (GMCSF) and granulocyte colonystimulating factor (GCSF) are example of cytokines specific to inflammation. Both cytokines
have been used to reflect ACD prevalence and progression.10,11
Stimulated by inflammatory cytokines, matrix metalloproteinases (MMPs) are partially
responsible for chronic articular cartilage degradation and can be used as pathogenic biomarkers.
MMP-3 and MMP-13 are 2 highly active MMP subtypes that play a role in ACD and have been
targeted for therapeutic intervention.12,13 MMP-3, also known as stromelysin-1, is one of the
most abundantly expressed MMPs. It is responsible for the activation of MMP-1 and MMP-13, 2
types of collagenases with the unique ability to cleave the triple helix of collagen, allowing other
proteinases to cause further degradation.38,39 Increased levels of MMP-3 and MMP-13 have been
found in synovial fluid of patients with chronic articular cartilage degradation when compared
with healthy controls.15,16
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Physical exercise is the most commonly recommended nonpharmacological intervention
for patients with chronic articular cartilage degradation.17 It is known to decrease disability and
pain associated with chronic ACD.18–20 Despite the prevalence of data that supports physical
exercise as a successful symptomatic treatment for degenerative joint disorders like ACD and
OA, the mechanism(s) underlying potential chondroprotective effects of exercise is(are) unclear.
Physical exercise appears to be capable of attenuating systemic low-grade inflammation
associated with a number of pathologic conditions including cardiovascular disease, diabetes,
and obesity.21 Additionally, we recently observed that a 30-minute running protocol decreased
knee intra-articular inflammation for a small pilot sample of young, able-bodied subjects,
indicating that running might protect articular cartilage for this demographic.22 Further, studies
show a significant change of serum MMP-3 concentration with running.23,24 However, it remains
unclear whether running can decrease knee-joint synovial fluid concentrations of inflammatory
cytokines MMP-3, and MMP-13 for all individuals—including those who are elderly, are obese,
or have suffered traumatic joint injury, such as an anterior cruciate ligament injury.
Anterior cruciate ligament injury reconstruction (ACLr) induces structural,25,26
biochemical,26,27 and biomechanical28,29 changes that increase the risk of articular cartilage
degradation up to 10 to 20 fold.30 For example, decreased collagen synthesis, diluted synovial
fluid, and increased (a) hemarthrosis, (b) cell necrosis, and (c) joint inflammation occur up to a
year after traumatic knee injury.27,31,32 Although some symptoms eventually subside, other
effects appear to be permanent (eg, diluted synovial fluid).33 The effect(s) that any, or all, of the
aforementioned changes might have on the influence of exercise on joint biochemistry and
corresponding/subsequent joint health is unclear. Evidence suggests that different loading
protocols contribute to unique changes of biomarkers of cartilage turnover and inflammation in
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the knee.34,35 This may suggest that populations with different loading patterns would similarly
have distinct biochemical changes in the knee. However, recent research has also shown that
moderate acute exercise stimulated a similar biochemical (inflammatory) response in both
injured and matched able-bodied controls. More research is needed to better understand the
effects of load on biochemistry of normal and abnormal (injured) cartilage so that more
supported conclusions can be made about the effects of load on articular cartilage health.
The purpose of this study was to evaluate how physical activity (an acute bout of
exercise: a 30-minute running protocol) affects knee-joint inflammation and degradation for
subjects with and without a history of ACLr. We hypothesized that running would decrease
inflammatory cytokines, MMP-3, and MMP-13 in knees of able-bodied subjects, but either not
change or increase inflammation in knees of ACLr subjects.
METHODS
Subjects
Four able-bodied recreational runners (3 men and 1 woman: 24 ± 2 years, 68 ± 7 kg, and
173 ± 9 cm) and 4 recreational runners who had undergone a unilateral ACL reconstruction (2
men and 2 women: 23 ± 1 years, 71 ± 6 kg, and 175 ± 4 cm) were recruited to participate in this
study. All subjects provided informed consent in accordance with the appropriate Institutional
Review Board and the Declaration of Helsinki.
ACLr participants were required to: (1) be between the ages of 18 and 30, (2) have a BMI
between 18.0 and 24.9, (3) be able to run at 3.0 m/s for 30 continuous minutes, (4) be engaging
in a minimum of 20 minutes of moderate physical activity 3 times a week, (5) have had a
unilateral ACL reconstruction surgery between 2 and 6 years before data collection, and (6) have

3

physician approval to return to unrestricted participation in physical activity. Each able-bodied
participant matched ACLr requirements 1 to 4.
The following criteria excluded participation from the ACLr group: (1) a lower extremity
injury or pain limiting physical activity for more than 2 months in the past 6 months, (2)
competing in athletic activities at the collegiate level, (3) balance or neuromuscular disorders, (4)
regular daily intake of any anti-inflammatory medication, (5) a previous knee injury prior to the
ACL tear that required surgery or limited physical activity for more than 3 months, or (6)
previous revisions of a previous ACL reconstruction. The following criteria excluded
participation from the able-bodied group: (1) ACLr group exclusion criteria 1 to 4 and (2) any
previous lower extremity surgery.
Experimental Design
Each participant completed 2 experimental sessions (exercise and unloading) in a
counterbalanced order, 1 week apart. For both experimental conditions, baseline synovial fluid
samples were collected at a local healthcare facility. Participants were then immediately
transported to a nearby university biomechanics laboratory. Participants remained in an unloaded
(seated) position during this transport. Approximately 15 minutes after the baseline samples were
collected, participants ran for 30 minutes at a self-selected speed of 3.0, 3.5, or 4.0 m/s (all
participants chose 3.0 m/s) on an AMTI (Watertown, MA, USA) treadmill. Immediately
following the run, subjects were seated in a wheelchair. Participants were then transported back
to the local health care facility, in an unloaded position (wheelchair), where a second synovial
fluid sample was taken approximately 30 minutes after the completion of the run. The control
session was identical to the run session except that the participants rested in an unloaded, seated
position in the laboratory for 30 minutes rather than running for 30 minutes.
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Synovial Fluid Sampling
Aspirations were taken from the lateral suprapatellar space of the participant’s affected
knee using a 10-mL syringe and 18-gauge, 1.5" hypodermic needle. Initially we attempted
(n = 2) to use an “incremental technique” as described by Driban et al,33 whereby ≤ 14 mL of
sterile saline was added to the joint in 2 mL increments until enough synovial fluid was
aspirated. We found that the time required to inject a sufficient amount of saline into the joint
was past the point of comfort for the participant. Instead, we standardized the protocol across the
remaining subjects (n = 6). The physician first attempted a traditional, ultrasound-guided
aspiration.33 If unsuccessful, a saline-assisted aspiration33 method was used by injecting 12 mL
of saline into the joint, and again attempting the aspiration.36 Once aspirated, proteiase inhibitor
was added and samples were stored on ice until the end of the session and stored at −80°C until
analysis.
Protein Concentration Standardization
In order to account for different amounts of saline in each sample, protein concentrations
were quantified and normalized. Total protein concentrations (all synovial fluid and, if present,
blood proteins) were measured using a Pierce Bicinchoninic Acid (BCA) Protein Assay Kit in
compliance with manufacturer’s parameters (Thermo Fisher Scientific, Waltham, MA, USA).
Many (15/32) of the synovial fluid samples were contaminated with blood. In an attempt
to estimate the level of blood contamination, hemoglobin concentrations were measured using a
Hemoglobin Colorimetric Detection Kit (Arbor Assays, Ann Arbor, MI, USA) following
manufacturer’s parameters. Blood volume was then estimated using Equation 1, under the
assumption that 150 mg of hemoglobin are in 1 mL of blood.37

5

Equation 1: Blood Volume (mL) =

mg
)×Sample Volume (mL)
mL
mg
150( )
mL

Hemoglobin Concentration (

Protein contamination from the blood was then calculated using Equation 2, under the
assumption that, on average, 1 mL of blood contains 70 mg of protein.38

mg

Equation 2: Blood Protein Contamination (mg) = Blood Volume (mL) × 70(mL)

Blood protein contamination was then subtracted from total synovial fluid protein concentrations
as measured using the aforementioned BCA assay.
Cytokine Analysis
A Magpix multiplexing platform (Luminex, Austin, TX, USA) was used for multianalyte
profiling of synovial fluid samples. Cytokines were measured using a 15-plex cytokine kit in
compliance with manufacturer’s parameters (EDM Millipore, Burlington, MA, USA). However,
instead of adding 25 µL of both sample and assay buffer into each respective well, we used the
aforementioned corrected total synovial fluid protein concentrations to calculate the needed
sample-to-assay buffer ratio to obtain 5 µg of protein from each sample in the 50 µL solution.
The cytokines we analyzed included the following: GCSF, GM-CSF, IFNg, IL-10, IL-12p40, IL13, IL-15, IL-1RA, IL-1β, IL-1α, IL-4, IL-6, IL-8, MIP-1β, and TNFα. The 5 μg of synovial
fluid sample was incubated overnight at 4°C with antibody-conjugated magnetic beads. The bead
complex was then washed and followed by a 1-hour incubation at room temperature on a plate
shaker in biotinylated detection antibody. Streptavidin–phycoerythrin was subsequently added
and samples were incubated for an additional 30 minutes on a plate shaker at room temperature.
A Magpix system was used to quantify bead complexes. All samples were run in duplicate. Two
quality controls were used to ensure the assay was working correctly. Cytokines that measured
below the lower limit of quantification in greater than half of the samples among the 8 subjects
were considered undetectable and not included in the analysis.
6

MMP Analysis
MMP-3 and MMP-13 were measured using a 2-plex MMP kit in compliance with
manufacturer’s parameters (EDM Millipore, Burlington, MA, USA). However, instead of adding
25 µL of both sample and assay buffer into each respective well, we used the aforementioned
corrected total synovial fluid protein concentrations to calculate the needed sample-to-assay
buffer ratio to obtain 5 µg of protein from each sample in the 50 µL solution. The 5 μg of
synovial fluid sample was incubated for 2 hours at room temperature with antibody-conjugated
magnetic beads. The bead-complex was then washed, followed by a 1-hour incubation at room
temperature on a plate shaker in biotinylated detection antibody. Like the cytokine analysis,
streptavidin–phycoerythrin was subsequently added and samples were incubated for an
additional 30 minutes on a plate shaker at room temperature. A Magpix system was used to
quantify bead-complexes. MMP-13 measured below the lower limit of quantification in greater
than half of the samples among the 8 subjects and was not included in the analysis.
Statistical Analysis
Both protein and cytokine concentration residuals were randomly scattered around zero
and therefore considered to be normally distributed. Mixed model analyses were used to
determine the main effects of session, case/control status, pre/post aspirations, and the
interactions between case/control status and pre/post aspirations. All statistical analyses were
conducted using JMP 13 Statistical Software (SAS Institute, Cary, NC, USA).
RESULTS
Cytokine Concentrations
Fourteen of 15 cytokines were undetectable across ≥ 75% of our samples. Granulocytecolony stimulating factor (GCSF) was detectable in each of the 32 samples. One of the samples
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was thrown out of the analysis, as it was 13 times higher than the second highest concentration of
GCSF (Table 1). We suspect that this outlier is a result of a pipetting error.
Changes in GCSF concentrations were highly variable in each of the unloading and
exercise sessions (Figure 1) and in both ACLr and able-bodied controls. We observed no
significant differences in the main effects of pretreatment and posttreatment aspirations (p =
0.45), case/ control status (p = 0.60) or session (p = 0.96).
MMP Concentrations
MMP-13 was undetectable across ≥ 75% of our samples. MMP-3 was detectable in 31 of
the 32 samples. The sample that measured below the detectable limit was indicated as the value
of the lowest point on the calibration curve (74 pg/mL) divided by 2 (37 pg/mL). A list of MMP3 concentrations is shown in Table 2.
Changes of MMP-3 concentration in both the unloading and exercise sessions are shown
in Figure 2. We observed no significant difference in synovial fluid protein concentrations
between pretreatment and posttreatment aspirations (p = 0.15), ACL and able-bodied control
groups (p = 0.85) or unloading and exercise sessions (p = 0.14).
DISCUSSION
The purpose of this project was to evaluate how a 30-minute run affects concentrations of
biomarkers of knee-joint articular cartilage degradation (specifically inflammatory cytokines and
MMPs) for subjects with and without a history of ACLr. We hypothesized that running would
decrease concentrations of these biomarkers in knees of able-bodied subjects and would either
not change or increase in subjects with a history of ACLr. We also hypothesized that these
biomarker concentrations would be higher at baseline in knees with a history of ACLr than knees
of able-bodied subjects. Our results suggest that there is no difference in inflammatory cytokine
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or MMP concentrations between normal, healthy and previously reconstructed knees following
either loading or unloading. However, due to the difficulty of extracting synovial fluid samples
from healthy joints, and our chosen saline dilution methodology, our assessment has major
limitations. In this study we also developed and implemented a novel approach to correct for
blood contamination of synovial fluid samples.
Cytokines: GCSF
Inflammation is known to be a predecessor of cartilage degeneration and a potential
indicator of joint health. In this study, granulocyte colony stimulating factor (GCSF) was the
only inflammatory cytokine from our panel that was detectable in all of our samples. It is an
anabolic cytokine and is activated by proinflammatory cytokines IL-1, IL-6, and TNFα.39 The
role of GCSF in articular cartilage health remains inconclusive; some evidence suggest that it
plays a positive role in articular cartilage health.
It has been reported that GCSF concentrations are decreased in OA synovial fluid when
compared to healthy controls (p < 0.05),40 and that injecting GCSF subcutaneously in rats
promoted faster cartilage repair.41 Further, an increase in blood serum GCSF concentration
corresponded with a significant (p = 0.04) decrease in pain for those with total knee arthroplasty
when compared to those that did not have a change in pain.42 This negative correlation between
synovial fluid concentration and serum concentration of biomarkers of ACD has been
demonstrated.22 It is speculated to be caused by the potential transfer of the biomarkers from the
synovial fluid into the blood serum.
In counterpoint, GCSF may instead have a negative effect on articular cartilage health as
it has been shown to act similarly to granulocyte macrophage colony stimulating factor
(GMCSF),43 a proinflammatory cytokine. GMCSF in synovial fluid is known to be significantly
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elevated in cases of knee OA44,45 and in cases of knee injury that precede knee OA.46 Some also
show that neutralization of GMCSF might effectively control OA pain and progression.47 In our
recent study we saw that a 30-minute run significantly (p = 0.03) decreased synovial fluid
GMCSF concentration,22 supporting the belief that physical activity reduces risk for OA.17
However, the results from this study demonstrated that there were no significant
differences in GCSF concentrations between ACL injured and uninjured subjects. Unfortunately,
our assessment of joint inflammation was limited to GCSF, as our chosen methodology (saline
dilution of synovial fluid) led to the unexpected finding that 15 of 16 biomarkers were
undetectable.
Matrix Metalloproteinases: MMP-3
MMPs are stimulated by proinflammatory cytokines and contribute to the degradation of
cartilage in both normal and pathologic conditions.48,14 MMP-3 was the one detectable of two
measured MMPs in our analysis. Studies have shown that serum MMP-3 concentrations increase
in the serum with running,23,24 with a positive correlation between speed and MMP-3
concentration.23 Accordingly, we expected to see (1) a significant decrease of synovial fluid
MMP-3 concentration after 30 minutes of running and either no change or a significant increase
after 30 minutes of unloading and (2) generally higher concentrations in ACLr participants
compared to able-bodied participants. The results from this study do not support our hypothesis,
as there were no statistically significant differences between sessions, pre/post aspirations, or
case/control status.
Possible explanations as to why our results differ from expectations are (a) our sample
size was too small to identify statistically significant results, (b) the 30-minute unloading and
exercise periods were not long and/or intense enough to elicit a statistically significant result, (c)
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the change of MMP-3 synovial fluid concentration does not occur within the 15-minute period
between the 30-minute session and aspiration, (d) a change of MMP-3 concentration occurs and
subsequently reverts to base level concentrations, or (e) joint health post-ACLr may greatly vary
between subjects due to an individualized reconstruction and/or rehabilitation causing
individualized responses to joint loading. These factors must be addressed before a strong
conclusion about the effects of joint loading (eg, running) on concentrations of MMP-3 can be
drawn.
Methodological Limitations
Synovial fluid cytokine concentrations have been successfully measured during a state of
high effusion with an associated increased volume of synovial fluid (eg, after injury or
surgery).49–51 Aspirations of noneffused, but pathological knees is still a novel approach,
successfully completed by only a few laboratory groups.11,52 Furthermore, the aspiration of
healthy (no symptomatic or radiographic evidence of OA), noneffused knees is even more
uncommon, with successful reports, as far as we have identified, coming from only two
laboratories.36,53 As determined by a previous study performed by our lab, it is very difficult to
obtain sufficient sample volume using the traditional aspiration method on healthy, noneffused
knees.22 Accordingly, we attempted a saline-assisted aspiration protocol based on the study by
Driban et al.36 They reported that a saline-assisted aspiration protocol may be a viable way to
measure biomarkers of OA in a noneffused, healthy knee.
In their study, Driban et al36 reported detectable levels of MMP-3, IL-13, IL-10, and IL1β. In our study, of these 4 biomarkers we measured detectable concentrations for only MMP-3.
Reasons vary for why the other 14 biomarkers (including IL-13, IL-10, and IL-1β) that we
measured were undetectable. It is possible that (1) the studied populations (ACLr and normal,
11

healthy knees) have lower concentrations than the OA population Driban et al measured and/or
(2) some cytokines that we analyzed are, in actuality, not present. Driban did use a slightly more
sensitive assay (SearchLight Proteome Multiplex Protein Array (Aushon BioSystems, Billerica,
MA, USA)), but we think that using the same assay would not have greatly affected our final
results.
This saline-assisted process is contrasted by the traditional technique used by our lab
group previously,22 which obtained straight, undiluted synovial fluid samples. The resulting pure
samples of synovial fluid allowed for complete analysis of 11 OA biomarkers. The difficulty
with this technique is that 1 in 5 aspirations were not successful, making it very difficult to
obtain enough complete sets of samples. Future studies might consider (a) a larger sample size,
(b) a longer/more intense exercise session, and (c) immediate and additional aspirations after the
30-minute session. Additionally, new approaches to concentrate saline-diluted synovial fluid
samples to ensure adequate protein concentration for analysis should be explored.
Correcting for Blood Contamination
A novel component of the preset study was the development of a method for controlling
for blood contamination in synovial fluid samples. Due to high protein concentration in blood, it
is difficult to measure synovial fluid dilution when there is blood in the sample. In previous
literature, samples of synovial fluid have been excluded from the study due to blood
contamination.36,54 Had we collected blood samples from each participant, we could have
measured individualized hemoglobin and total protein concentrations (as found in Equations 1
and 2) without making any assumptions. Yet, even without the addition of the blood draw, our
approach may be viable to control for blood contamination in synovial fluid samples.
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CONCLUSION
Two (GCSF and MMP-3) of the 17 measured biomarkers were detectable. There were no
significant differences in either GCSF or MMP-3 due to a 30-minute run or 30-minute unloading
period in either the able-bodied or ACLr participants. Further, there were no significant
differences between biomarker concentrations and case-control status. It is difficult to draw
additional strong conclusions from our study as we were not able to comprehensively test our
hypothesis (many cytokines were undetectable). A novel method of controlling for blood
contamination in synovial fluid samples was implemented. Future research aimed at identifying
ways to successfully obtain and measure synovial fluid samples from noneffused knees should
be conducted.
CONFLICT OF INTEREST
The authors report no conflict of interest.
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Table 1: Concentrations of Granulocyte-colony stimulating factor (GCSF) before and after each
unloading and exercise session. *This sample was thrown out.
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Table 2 : Concentrations of MMP-3 before and after each unloading and exercise session.
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Figure 1: GCSF concentrations do not significantly change following a 30-minute (A) unloading
or (B) exercise session in either the ACLr or control group.
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Figure 2: MMP-3 concentrations do not significantly change following a 30-minute (A)
unloading or (B) exercise session in either the ACLr or control group.
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